Literature DB >> 11691821

Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine.

Y M Dupertuis1, M Vazquez, J P Mach, N De Tribolet, C Pichard, D O Slosman, F Buchegger.   

Abstract

Use of radiolabeled nucleotides for tumor imaging is hampered by rapid in vivo degradation and low DNA-incorporation rates. We evaluated whether blocking of thymidine (dThd) synthesis by 5-fluoro-2'-deoxyuridine (FdUrd) could improve scintigraphy with radio-dThd analogues, such as 5-iodo-2'-deoxyuridine (IdUrd). We first show in vitro that coincubation with FdUrd substantially increased incorporation of [125I]IdUrd and [3H]dThd in the three tested human glioblastoma lines. Flow cytometry analysis showed that a short coincubation with FdUrd (1 h) produces a signal increase per labeled cell. We then measured biodistribution 24 h after i.v. injection of [125I]IdUrd in nude mice s.c. xenografted with the three glioblastoma lines. Compared with animals given [125I]IdUrd alone, i.v. preadministration for 1 h of 10 mg/kg FdUrd increased the uptake of [125I]IdUrd in the three tumors 4.8-6.8-fold. Compatible with previous reports, there were no side effects in mice observed for 2 months after receiving such a treatment. The tumor uptake of [125I]IdUrd was increased < or =13.6-fold when FdUrd preadministration was stepwise reduced to 1.1 mg/kg. Uptake increases remained lower (between 1.7- and 5.8-fold) in normal proliferating tissues (i.e., bone marrow, spleen, and intestine) and negligible in quiescent tissues. DNA extraction showed that 72-80% of radioactivity in tumor and intestine was bound to DNA. Scintigraphy of xenografted mice was performed at different times after i.v. injection of 3.7 MBq [125I]IdUrd. Tumor detection was significantly improved after FdUrd preadministration while still equivocal after 24 h in mice given [125I]IdUrd alone. Furthermore, background activity could be greatly reduced by p.o. administration of KClO4 in addition to potassium iodide. We conclude that FdUrd preadministration may improve positron or single photon emission tomography with cell division tracers, such as radio-IdUrd and possibly other dThd analogues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11691821

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Novel 99mTc-labelled complexes with thymidine isocyanide: radiosynthesis and evaluation as potential tumor imaging tracers.

Authors:  Xiaojiang Duan; Xuran Zhang; Qianqian Gan; Si'an Fang; Qing Ruan; Xiaoqing Song; Junbo Zhang
Journal:  Medchemcomm       Date:  2018-03-06       Impact factor: 3.597

Review 2.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

3.  Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine.

Authors:  Florence Perillo-Adamer; Angelika Bischof Delaloye; Céline S Genton; Andreas O Schaffland; Yves M Dupertuis; Franz Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

4.  Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.

Authors:  David Viertl; Angelika Bischof Delaloye; Bernard Lanz; Carole Poitry-Yamate; Rolf Gruetter; Vladimir Mlynarik; Simon M Ametamey; Tobias L Ross; Hans-Anton Lehr; Pierre-Alain André; Florence Perillo-Adamer; Marek Kosinski; Yves M Dupertuis; Franz Buchegger
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

5.  First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.

Authors:  Shivaani Kummar; Larry Anderson; Kimberly Hill; Eva Majerova; Deborah Allen; Yvonne Horneffer; S Percy Ivy; Larry Rubinstein; Pamela Harris; James H Doroshow; Jerry M Collins
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.